Denmark’s Serendex achieves full subscription on rights issue
Serendex Pharmaceuticals, the Danish healthcare company, has completed its Nkr111.8m ($12.5m) rights issue, having achieved full subscription.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts